Printer-friendly version

Detailed Program

Monday, 12 September | Tuesday, 13 September | Wednesday, 14 September | Thursday, 15 September

Monday, 12 September (back to top)

16:00 – 17:10

Special Session

Ballroom A, Level 22

16:00 – 16:10

Pratap Singhasivanon
2011 Conference Chair
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand

 

16:10 – 16:20

José Esparza

Global HIV Vaccine Enterprise

Acting President of the Board

Bill & Melinda Gates Foundation

Seattle, WA, USA 

 

16:20 – 16:40

Are There Lessons From Past Vaccines for an AIDS Vaccine?

 Presentation Slides
Stanley Plotkin
University of Pennsylvania
Doylestown, PA, USA

SS01.01

16:40 – 17:10

Moving Forward from RV144: An Industrial Perspective

 Presentation Slides
Sanjay Gurunathan
sanofi pasteur
Swiftwater, PA, USA

SS01.02

17:10 - 18:40

Poster Session 01 and Welcome Reception

Ballroom B, Level 22

 

All posters ending in odd numbers were presented in Poster Session 01.

Tuesday, 13 September (back to top)

08:30 – 10:00

Opening Ceremony

Ballroom A, Level 22

8:30 - 08:45

Doors Opened. Entertainment Provided by

Mahidol University Orchestra

 
09:00 – 09:20

Her Royal Highness
Princess Maha Chakri Sirindhorn


09:20 – 09:50

Progress Towards an HIV 

Vaccine – Lessons Learned

from HIV Prevention

Presentation Slides

Carl Dieffenbach

Division of AIDS, NIAID, NIH

Bethesda, MD, USA

OC01.01

10:00 – 10:30

Tea and Coffee Break

Ballroom B, Level 22

10:30 – 12:30

Plenary Session 01:
Novel Approaches in Clinical Evaluation through Global Collaboration

Ballroom A, Level 22

10:30 – 10:45

Africa's Contribution to AIDS Vaccine Research and Development

 Presentation Slides
Pontiano Kaleebu
MRC/UVRI Research Unit on AIDS
Entebbe, Uganda

PL01.01

10:45 – 11:00

Thailand's Contribution to HIV Vaccine Research and Development

 Presentation Slides
Punnee Pitisuttithum
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

PL01.02

11:00 – 11:30

Update on RV144: Correlates, Sieve Analysis, and Clinical Development

 Presentation Slides
Jerome Kim     
Walter Reed Army Institute of Research (WRAIR)
Rockville, MD, USA

PL01.03

11:30 – 12:00

Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward

 Presentation Slides
Barton Haynes           
Duke Human Vaccine Institute
Durham, NC, USA

PL01.04

12:00 – 12:30

Vaccines Beyond RV144 Poxvirus Vector-Based HIV 

 Slides Unavailable
Giuseppe Pantaleo
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland

PL01.05

12:30 – 13:30

Lunch Break

Ballroom B, Level 22

13:30 – 15:00

Oral Abstract Session 01:
Vaccines and Other Prevention Strategies

Ballroom A, Level 22

13:30 - 13:45

DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa

 Presentation Slides
M Perreau, HC Welles, A Harari, O Hall, R Martin, M Maillard, G Dorta, P Bart, EJ Kremer, J Tartaglia, R Wagner, M Esteban, Y Levy, G Pantaleo

OA01.01

13:45 - 14:00

Cell-Mediated Immune Responses After DNA Delivered by Either Biojector or Electroporation and Boosted with a Heterologous Insert Recombinant Poxvirus

 Presentation Slides
JR Currier, S Ratto-Kim, V Ngauy, J Ake, C Lau, T Doris, E Herrera, WB David, NY Sardesai, J Boyer, AS Khan, J Lee, M Bagarazzi, J Yan, E Adams, P Earl, B Moss, J Kim, N Michael, M Robb, MA Marovich

OA01.02

14:00 - 14:15

Titered Mucosal Challenge of Rhesus Macaques with SIVmac251 Recapitulates HIV Vaccine Efficacy in Humans

 Slides Unavailable
G Franchini, P Pegu, M Vaccari, S Gordon, B Keele, M Doster, Y Guan, G Ferrari, D Montefiori, D Venzon, C Fenizia, J Lifson, N Michael, J Kim, J Tartaglia

OA01.03

14:15 - 14:30

Preservation of HIV-1-Specific CD4+ T-IFNγ-Cell Responses in Intercurrent Infections Following Exposure to Tenofovir Gel

 Slides Unavailable
M Mureithi , D Poole, V Naranbhai, S Reddy, Np Mkhwanazi, S Sibeko, Q Abdool Karim, S abdool Karim, T Ndung'u, M Altfeld,   CAPRISA 004 Trial Group

OA01.04

14:30 - 14:45

Homologous Priming and Boosting with Recombinant MVA, Prevention of Infection as Good as With the Heterologous Regimen of DNA Priming and MVA Boosting

 Slides Unavailable
HL Robinson, L Lai, S Kwa, PA Kozlowski, V Hirsch, BK Felber, GN Pavlakis, PL Earl, B Moss, RR Amara

OA01.05

14:45 - 15:00

Extended Evaluation of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E

 Presentation Slides
S Rerks-Ngarm, RM Paris, S Chunsutthiwat, N Premsri, C Namwat, J Bowornwatanuwong, S  Li, J Kaewkungkal, R Trichavaroj, M de Souza, D Francis, E Adams, S Gurunathan, J Tartaglia, R O'Connell, C Eamsila, S Nitayaphan, V Ngauy, P Thongcharoen, P Kunasol, N Michael, M Robb, P Gilbert, J Kim

OA01.06 LB

13:30 – 15:00

Oral Abstract Session 02:
Innate Immunity

Lotus 1-4, Level 22

13:30 - 13:45

Innate Immune Response Signatures to Ad5 (HVTN 071) and MVA (HVTN 205/908) Vectored Candidate HIV Vaccines Predict Induction of Adaptive Responses

 Slides Unavailable
E Andersen-Nissen, DE Zak, AC Duerr, JT Chang, ER Peterson, AT Krishnamurty, TR Hensley, DJ Adams, MK Hamilton, J Li, A Sato, CA Morgan, ML Elizaga, SC DeRosa, PA Goepfert, HL Robinson, A Aderem, MJ McElrath

OA02.01

13:45 - 14:00

 Frequent and Strong NK Responses to HIV-1 Env Peptides in Individuals with Acute and Chronic HIV-1 Infection

Slides Unavailable

CF Thobakgale, L. Fadda, K. Lane, F. Pereyra,

B.D. Walker, T. Allen, M. Altfeld

OA02.02

14:00 - 14:15

NKp46 and NKG2D Receptors Are Implicated in the Priming and Suppression of HIV Replication by Natural Killer Cells Stimulated by MVA/HIV ANRS Vaccine

 Slides Unavailable
J Cummings, V Arnold, C Didier, A Gilbert, K Yarbrough, Y Levy, F Barré-Sinoussi, D Scott-Algara

OA02.03

14:15 - 14:30

HIV Infection Eliminates the Antibody-Dependent Cellular Cytotoxicity (ADCC) Functional Advantage of KIR3DL1-Expressing NK Cells from HLA-Bw4 Carriers

 Slides Unavailable
MS Parsons, L Wren, G Isitman , M Navis, I Stratov, NF Bernard, SJ Kent

OA02.04

14:30 - 14:45

Inhibition of Human Immunodeficiency Virus Type 1 Infection of Human Monocyte-Derived Macrophages by Anti-Lipid and Anti-MPER Monoclonal Antibodies

 Slides Unavailable
M Rao, O Jobe, KK Peachman, GR Matyas, LV Asher, CR Alving

OA02.05

14:45 - 15:00

JAK3 Inhibition In Vivo in Chronically SIV Infected Rhesus Macaques Deplete NK-17 Cells

 Presentation Slides
L Kowawisatsut, AA Ansari, K Pattanapanyasat

OA02.06 LB

13:30 – 15:00

Oral Abstract Session 03:
Novel Immunogens and Inserts

Lotus 5-7, Level 22

13:30 - 13:45

Targeting Antigen to CD40 on Dendritic Cells Mediates Expansion of Multi-Epitope HIV-Specific Polyfunctional CD4+ and CD8+ T Cells

 Slides Unavailable
A Flamar, Y Xue, S Zurawski, S Oh, M Montes, A Montes, B King, L Sloan, J Banchereau, Y Levy, G Zurawski

OA03.01

13:45 - 14:00

Identification of Escape-Refractory Subdominant CD8 Epitopes for Common HLA Alleles

 Presentation Slides
CL Boutwell, C Oniangue-Ndza, A Schneidewind, H Streeck, A Seese, E Mellors, K Murthy, K Power, M Kemper, T Dudek, BD Walker, M Altfeld, TM Allen

OA03.02

14:00 - 14:15

HIV-1 gp120 V1V2-Scaffolds for Structural Analysis and Immunogen Design

 Presentation Slides
J McLellan, M Pancera, K Dai, J Boyington, Z Yang, C Carrico, S Shahzad-ul-Hussan, M Sastry, S Schmidt, Y Yang, M Bonsignori, B Haynes, S Phogat, C Bewley, J Mascola, W Schief, G Nabel, P Kwong

OA03.03

14:15 - 14:30

Identification of Mimotopes for Neutralizing Antibodies from Elite Controllers with Env-Tailored Phage Display Libraries

 Slides Unavailable
M Zhou, S Koch, T Meyer, B Brill, M Sakarellos-Daitsiotis,   Miguel Benito,   Soriano, A Haberl, M Bickel, H von Briesen, M Hust, U Dietrich

OA03.04

14:30 - 14:45

Role of Hypervariable Loops in Intersubunit Associations of Env:  Trimeric gp140 Immunogen as a Platform for Novel Epitope Display

 Slides Unavailable
H Cheng, CG Moscoso, L Xing, L Martin, S Barnett, I Srivastava

OA03.05 LB

14:45 - 15:00

Development and Characterization of HIV-1 Virus-like Particles Produced by Stably Transfected Drosophila S2 cells

 Slides Unavailable
L Yang, Y Song, P Zhu, P Zhou

OA03.06

15:00 – 15:30

Tea and Coffee Break

Ballroom B, Level 22

15:30 – 17:15

Oral Abstract Session 04:
Novel Monoclonals and Structural Insights 

Ballroom A, Level 22

15:30 - 15:45

Potent and Broad Neutralization by a CD4 Binding Site Monoclonal Antibody from an HIV-1 Infected Donor

 Slides Unavailable
E Falkowska, DR Burton, P Poignard, J Mascola, PD Kwong, X Wu

OA04.01

15:45 - 16:00

Human Anti-V2 Monoclonal Antibodies Neutralize Tier 1 HIV-1 Pseudoviruses

 Slides Unavailable
MK Gorny, C Williams, T O'Neal, X Wang, MS Seaman, S Zolla-Pazner

OA04.02

16:00 - 16:15

2F5-like Cross-Reactive HIV-1-Neutralizing Monoclonal Antibodies with Low Number of Somatic Mutations

 Presentation Slides
Z Zhu, HR Qin, W Chen, Q Zhao, X Shen, R Schutte, Y Wang, G Ofek, E Streaker, P Prabakaran, GG Fouda, H Liao, J Owens, M Louder, Y Yang, K Klaric, MA  Moody, JR Mascola, JK Scott, PD Kwong, D Montefiori, BF Haynes, GD Tomaras, DS Dimitrov

OA04.03

16:15 - 16:30

Characterization of CD4-Binding Site Directed Monoclonal Antibodies Isolated from HIV-1 gp140 Env Immunized Rhesus Macaques

 Presentation Slides
C Sundling, Y Li, N Huynh, R Wilson, S O'Dell, JR Mascola, RT Wyatt, GB Karlsson Hedestam

OA04.04

16:30 - 16:45

Structural Insights into HIV-1 Neutralization by New Highly Potent and Broadly Neutralizing Antibodies

 Slides Unavailable
J Julien, R Pejchal, L Kong, RS Stanfield, J Lai, LM Walker, KJ Doores, M Huber, E Falkowska, P Poignard, SK Phogat, WC Koff, DR Burton, IA Wilson

OA04.05

16:45 – 17:00

AAV2/8-Encoded Vaccine Expressing a Broadly Neutralizing HIV Antibody Protects Humanized Mice from High-Dose Intravenous Viral Challenge

 Slides Unavailable
AB Balazs, J Chen, CM Hong, DS Rao,

L Yang, D Baltimore

OA04.06

17:00 – 17:15

Evolution of HIV-1 Transmitted/Founder Viruses Results in the Formation of Epitopes for Later Broadly Rross-Neutralizing Antibodies

 Presentation Slides
PL Moore, ES Gray, T Hermanus, D Sheward, N Tumba, CK Wibmer, J Bhiman, S Sibeko, SS Abdool Karim, C Williamson, L Morris

OA04.07 LB

15:30 – 17:00

Oral Abstract Session 05:
Acute Infection/Viral Diversity 

Lotus 1 – 4, Level 22

15:30 - 15:45

HIV-Specific Cytolytic CD4+ T-Cell Responses During Acute HIV-1 Infection Predict Disease Outcome

 Slides Unavailable
DZ Soghoian, H Jessen, S Cutler, M Flanders, S Ranasinghe, M Lindqvist, I Davis, K Lane, J Rychert, ES Rosenberg, BD Walker, H Streeck

OA05.01

15:45 - 16:00

Control of Acute HIV-1 Subtype C Viremia Is Associated with Limited CD8+ T-Cell Immunogenicity

 Slides Unavailable
MA Radebe, K  Nair, F Chonco, K Bishop, K Bishop, JK Wright, M van der Stok, Z Mncube, M Altfeld, BD Walker, T  Ndung'u

OA05.02

16:00 - 16:15

Lymphocyte Dynamics in Acute HIV-1 Infection: RV217-The Early Capture HIV Cohort Study (ECHO)

 Slides Unavailable
L Eller, M Eller, A Eser, P Naluyima, K Shikuku, A Taylor, E Rono, S Sukwit, S Nitayaphan, J Currier, M de Souza, S Peel, J Kim, N Michael, M Marovich, M Robb

OA05.03

16:15 - 16:30

Long-Lived Historical Record of Evolution of Viral Diversity in Peripheral Blood Cells by Deep Pyrosequencing

Slides Unavailable 
L Yin, L Liu, Y Sun, W Hou, AC Lowe, M Salemi, WG Farmerie, JW Sleasman, MM Goodenow

OA05.04

16:30 - 16:45

Dynamics of HIV-1 Subtype C Gag in the Global Epidemic

 Presentation Slides
V Novitsky, R Wang, M Essex

OA05.05

16:45 - 17:00

Important Contribution of Subdominant HIV-Specific CD8 T Cell Responses to Early Control of HIV Replication

 Presentation Slides
H Streeck, D Kwon, M Addo, M Flanders, I Davis, S Cutler, J Rychert, K Lane, B Yassine-Diab, J Routy, S Little, H Jessen, A Kelleher, F Hecht, R Sekaly, E Rosenberg, B Walker, T Allen, M Altfeld

OA05.06

15:30 – 17:00

Oral Abstract Session 06:
T-Cell Immunity and Immune Escape

Lotus 5 - 7, Level 22

15:30 - 15:45

Deconstructing HIV-Specific CD8+T Cell Responses in HIV Elite Controllers

 Slides Unavailable

ZM Ndhlovu, LB Chibnik, J Proundfoot, S Vine, F Porichis, A McMullen, K Cesa, A Piechocka-Trocha, PL De Jager, DE Kaufmann, BD Walker

OA06.01

15:45 - 16:00

Ontogeny of CD8+ T Cells in Acute HIV-1 that Inhibit Autologous and Heterologous Transmitted/Founder (T/F) Viruses

 Slides Unavailable
SA Freel, RA Picking, G Ferrari, C Ochsenbauer, JC Kappes, J Kirchherr, KJ Weinhold, K Soderberg, AJ McMichael, BF Haynes, GD Tomaras

OA06.02

16:00 - 16:15

The RV144 Vaccine Induced CD4+ T Cells Producing Th1 and Th2 Cytokines with Proliferative Potential

 Presentation Slides
S DeRosa, N Frahm, OD Defawe, D Carter, EP Thomas, R Smith, R Gottardo, N Kochar, H Janes, Y Fong, X Yu, NL Michael, JH Kim, S Rerks-Ngarm, MJ McElrath

OA06.03

16:15 - 16:30

Association of Timing of HLA B*8101 and B*3910 Mediated p24 Sequence Evolution and Pathways to CTL Escape with Disease Progression

 Presentation Slides
RS Ntale, DR Chopera, N Ngandu, D Debra, M Mlotshwa, CM Gray, K Mlisana , S Abdool Karim, C Williamson, The CAPRISA 002 Study Team

OA06.04

16:30 - 16:45

Evidence of HIV-Specific ADCC Immune Escape

 Presentation Slides
AW Chung, G Isitman, M Navis, M Kramski, RJ Center, SJ Kent, I Stratov

OA06.05

16:45 - 17:00

Imbalance Between T Helper Type 17 and T Regulatory Cells: Implications for HIV Pathogenesis

 Slides Unavailable
D Li, J Chen, M Jia, K Hong, Y Ruan, H Liang, H Peng, P Ma, Y Shao

OA06.06

17:15 – 21:30

Banquet at the Royal Navy Hall

Wat Arun, Bangkok Yai

Wednesday, 14 September (back to top)

08:30 – 10:00

Plenary Session 02:
New Prevention Strategies

Ballroom A, Level 22

08:30 – 09:00

Voluntary Medical Male Circumcision for HIV Prevention:  What Are the Lessons for Other Prevention Strategies?

Presentation Slides
Helen Weiss
London School of Hygiene & Tropical Medicine
London, United Kingdom

PL02.01

09:00 – 09:30

Lessons Learnt from HIV Pre- And Post-Infection Studies: Implications for Combination Prevention Strategies

Presentation Slides
Carolyn Williamson
University of Cape Town
Cape Town, South Africa

PL02.02

09:30 – 10:00

What's New in Preventing Mother-to-Child HIV-1 Transmission (MTCT)

Presentation Slides
Lynne Mofenson
National Institute of Child Health and Development, National Institutes of Health
Rockville, MD, USA

PL02.03

10:00 – 10:30

Tea and Coffee Break

Ballroom B, Level 22

10:30 – 12:30

Symposia 01:
Bridging and Sustaining Community Partners in AIDS Vaccine Research

Ballroom A, Level 22

10:30 – 10:54

Combination Prevention Where Clinical Trials and Public Health Are at Crossroads

Presentation Slides

A. Cornelius Baker
NIAID HIV Vaccine Research Education Initiative/FHI
Washington, DC, USA

S01.01

10:54 – 11:18

Changing Standards of Care in South Africa: Considerations for HIV Vaccine Trials

Presentation Slides

Glenda Gray
Perinatal HIV Research Unit
Soweto, South Africa

S01.02

11:18 – 11:42

Community Engagement for Care in HIV Vaccine Trials: An Exploration of Ethical Considerations and Stakeholder Practices/Perspectives 

Slides Unavailable

Catherine Slack
HIV AIDS Vaccines Ethics Group UKZN
Pietermaritzburg, South Africa

S01.03

11:42 – 12:06

In it for the Long Run: Calibrating Community Engagement Efforts to Local Contexts and New Challenges

Presentation Slides

Alexandre Menezes
International AIDS Vaccine Initiative
Rio de Janeiro, Brazil

S01.04

12:06 – 12:30

Funding and Sustaining Community Engagement Science – Partnerships, Politics and Power

Presentation Slides

Steven Wakefield
HIV Vaccine Trials Network
Seattle, WA, USA

S01.05

10:30 – 12:30

Oral Abstract Session 07:
B Cell Immunology

Lotus 5 - 7, Level 22

10:30 - 10:45

Bispecific Fusion Antibodies PG9-Ibalizumab (PG9-iMab) and VRC01-Ibalizumab (VRC01-iMab) Exhibit 100% Breadth and Picomolar Potency

Presentation Slides

CS Pace, R Song, D Franco, M Seaman, DD Ho

OA07.01

10:45 - 11:00

Identification of Amino Acid Residues in HIV-1 Envelope Targeted by Plasma Broadly Neutralizing Antibodies using Evolutionary Models

Presentation Slides

M Lacerda, PL Moore, N Ngandu, ES Gray, K Wibmer, M Nonyane, D Sheward, BT Korber, DC Montefiori, C Williamson, L Morris, C Seoighe

OA07.02

11:00 - 11:15

Isolation of a Subset of Novel HIV-1 Broadly Neutralizing Antibodies with Dual Specificity Overlapping the Env Receptor and Coreceptor Binding Sites

Slides Unavailable

Y Li, S O'Dell, X Wu, S Schmidt, C Hogerkorp, Y Feng, B Chakrabarti, R Wilson, N Longo, N Doria-Rose, M Roederer, M Connors, R Wyatt, J Mascola

OA07.03

11:15 - 11:30

Neutralizing Antibodies Inhibit HIV-1 Transfer from Dendritic Cells to Primary CD4 T Lymphocytes

Slides Unavailable

B Su, K Xu, M Peressin, A Lederle, S Schmidt, G Laumond, C Moog, V Holl

OA07.04

11:30 - 11:45

Induction of Neutralizing Antibody Responses in HIV Infection Is Associated with HIV-Specific CD4 T Cell Responses

Slides Unavailable

M Mueller, M Lindqvist, D Soghoian, S Ranasinghe, T Wrin, P Phung, S Deeks, C Pilcher, F Hecht, H Streeck

OA07.05

11:45 - 12:00

Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization

Presentation Slides

BK Brown, L Wieczorek, G Kijak, K Lombardi, J Currier, M Wesberry, C Ochsenbauer, JC Kappes, V Ngauy, M Marovich, N Michael, DC Montefiori, VR Polonis

OA07.06

12:00 - 12:15

The Effect of HIV-1 Superinfection on the Development of Neutralizing Antibody Breadth Among Female Sex Workers in Mombasa, Kenya

Presentation Slides

VC Cortez, J Overbaugh

OA07.07

12:15 - 12:30

The Thai Phase III Clinical Trial (RV144) Induces the Generation of Antibodies That Target a Conserved Region Within the V2 Loop of GP120

Presentation Slides

N Karasavvas, E Billings, M Rao, J Currier, NL Michael, S Rerks-Ngarm, P Pitisuttithum, J Kaewkungwal, V Ngauy, S Nitayaphan, S Madnote, D  Arworn, J Kim, M de Souza

OA07.08 LB

10:30 – 12:30

Oral Abstract Session 08:
Animal Models and HIV Transmission

Lotus 5 - 7, Level 22

10:30 - 10:45

Evidence for CD4 T-Cell Mediated Immune Control of Macrophage Infection in Rhesus Macaques Undergoing CD4+ Lymphocyte Depletion Prior to SIV Infection

Presentation Slides

A Ortiz, B Li, NR Klatt, B Lawson, E Ryzhova, P Carnathan, M Paiardini, J Else, F Gonzalez-Scarano, SJ Ratcliffe, J Brenchley, J Estes, C Derdeyn, G Silvestri

OA08.01

10:45 - 11:00

CD4+ T Cell Escape in a SIVmac239-Infected Indian Rhesus Macaque Elite Controller with Breakthrough Viremia

Presentation Slides

J Giraldo-Vela, FA Norante, AT Bean, EJ Leon, R Rudersdorf, NA Wilson, DI Watkins, JB Sacha

OA08.02

11:00 - 11:15

Decreased Penetration of GFP-Labeled Lentiviral Particles in the Vagina and Endocervix of SIV∆3-Vaccinated Macaques

Slides Unavailable

A Carias, M Anderson, E Okocha, M McRaven, W Li, RP Johnson, T Hope

OA08.03

11:15 - 11:30

Long-Term Programming of Antigen-Specific Immunity from Gene Expression Signatures in the PBMC of Rhesus Macaques Immunized with an SIV DNA Vaccine

Slides Unavailable

JD Boyer, SE  Belisle, J Yin, DJ Shedlock, A Dai, J Yan, MG Lewis, H Andersen, JA Karl, DH O'Connor, A Khan, N Sardesai, RE Palermo, DB Weiner, MG Katze

OA08.04

11:30 - 11:45

Compromised NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Chronic SIV Infection

Slides Unavailable

X He, Z Luo, M Jia, Y Li, Z Cong, D Li, H Liang, Y Shao

OA08.05

11:45 - 12:00

Cytotoxicity Capacity of SIV-Specific CD8+ T Cells Against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques

Presentation Slides

D Mendoza, S Johnson, B Peterson, N Doria-Rose, G Franchini, D Schneider, MT Trivett, CM Trubey, V Coalter, DI Watkins, JD Lifson, SA Migueles, M Connors

OA08.06

12:00 - 12:15

Live Attenuated Influenza-SIV Vaccines: Efficacy Against Mucosal Challenge in Macaques

Slides Unavailable

SJ Kent, S Jegaskanda, J Reece, T Ameresena, A Sexton, C Fernandez, J Stambas, A Brooks, R De Rose

OA08.07

12:15 - 12:30

Reduction of Founder Virus in Vaccinated Monkeys after Mucosal SIV Challenge.

Slides Unavailable

JB Whitney, M Rolland, M Lacerda, PT Hraber, A DeCamp, C Luedemann, SS Rao, JR Mascola, B  Korber, G  Nabel, P Gilbert, C Seoighe, NL  Letvin

OA08.08 LB

15:00 – 16:00

Lunch Break

Young and Early-Career Investigators Networking Lunch

Lunch tables in Ballroom B have been reserved for young and early career investigators to network with senior researchers. A list of featured researchers is available at the registration desk.

Ballroom B, Level 22

13:30 – 15:00

Oral Abstract Session 09:
Pre-Clinical and Early Clinical Trials

Ballroom A, Level 22

13:30 - 13:45

T-Cell Responses Induced by Immunization with Ad35-HIV-1 Vaccines Are Broad, Durable, Polyfunctional and Can Mediate Inhibition of HIV

Presentation Slides

JH Cox, P Hayes, E Cormier, D Gill, J Kopycinski, A Spentzou, L Hachaambwa, C Bunce, E Sayeed, A Lombardo, W Komaroff, K Loughran, B Barin, L Dally, J Ackland, T Tarragona, M Keefer, J Excler, P Fast, J Gilmour

OA09.01

13:45 - 14:00

ADCC Titers to HIV-Infected Cells Are Detectable in the Majority of Vaccine Recipients in the RV144 Trial

Presentation Slides

MD Alpert, JD Harvey, WJ Neidermyer, Y Huang, D Morris, L Harris, H Gao, DC Montefiori, P Pitisuttithum, J Kaewkungwal, S Nitayaphan, S Rerks-Ngarm, NL Michael, JH Kim, DT Evans


OA09.02

14:00 - 14:15

Polyfunctional CD4/CD8 HIV-Specific Cytokine Responses and Presence of Cytolytic Markers in Swedish Vaccinees Immunized with HIV-1 DNA and HIV-1 MVA

Slides Unavailable

K Godoy-Ramirez, C Nilsson, K Karlén, T Tecleab, M Marovich, B Hejdeman, B Wahren, E  Sandström, G Biberfeld

OA09.03

14:15 - 14:30

Surface Plasmon Resonance Analysis of Anti-gp120 V2-Specific IgG Antibodies Generated in the RV144 Thai Trial

Slides Unavailable

EA Billings, N Karasavvas, MS de Souza, J Currier, P Pitisuttithum, J Kaewkunwal, S Nitayaphan, PB Gilbert, GD Tomaras, SB Zolla-Pazner, BF Haynes, NL Michael, S Rerks-Ngarm, JH Kim, M Rao

OA09.04

14:30 – 14:45

V2-Reactive Antibodies in RV144 Vaccinees' Plasma

Slides Unavailable

S Zolla-Pazner, T Cardozo, A deCamp, B Haynes, J Kim, X Kong, N Michael, S Rerks-Ngarm, C Williams

OA09.05

14:45 - 15:00

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine,MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers

Presentation Slides

MO Afolabi, J Ndure, J Mueller, V Thomas, M Shams-Rony, N Borthwick, A Bridgeman, A Black, M Reilly, W Jaoko, G John-Stewart, G Ambler, B Lohman-Payne, T Hanke, KL Flanagan

OA09.06

13:30 – 15:00

Oral Abstract Session 10:
B Cell Vaccine Concepts

Lotus 1 - 4, Level 22

13:30 - 13:45

Eliciting Broadly Neutralizing Antibodies Against HIV-1 Using a Novel Antigen Containing gp41 Membrane-Proximal External Region

Slides Unavailable

D Han, H Habte, Y Qin, K Takamoto, C Labranche, D Montefiori, M Cho

OA10.01

13:45 - 14:00

Neutralizing Antibody Responses Induced with V3-Scaffold Protein Boosts Following Priming with gp120 DNA

Presentation Slides

S Zolla-Pazner, X Kong, X Jiang, T Cardozo, A Nadas, S Cohen, M Totrov, MS Seaman, S Wang, S Lu

OA10.02

14:00 - 14:15

Phase I "Proof of Principle": Immunization with Virosome-Gp41-Derived Antigen Induces Mucosal Antibodies with Antiviral Properties

Slides Unavailable

G Leroux-Roels, C Maes, F Clement, F van Engelenburg, M van den Dobbelsteen, R Zurbriggen, M Amacker, M Adler, M Spengler, J Detmers, F Anjuere, L Lopalco, D Tudor, A Drillet, M Bomsel, A Chalifour, S Fleury

OA10.03

14:15 - 14:30

DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660

Presentation Slides

R Jalah, V Patel, V Kulkarni, A Valentin, C Alicea, M Rosati, A von Gegerfelt, NY Sardesai, J Bess, Jr., JD Lifson, B Keele, RR Amara, HL Robinson, VM Hirsch, Y Guan, D Venzon, DC Montefiori, BK Felber, GN Pavlakis

OA10.04

14:30 - 14:45

Direct Antibody Access to the HIV-1 MPER Positively Correlates with Neutralization Sensitivity

Presentation Slides

BK Chakrabarti, LM Walker, JF Guenaga, A Ghobbeh, P Poignard, DR Burton, RT Wyatt

OA10.05

14:45 - 15:00

A DNA Prime/Protein Boost Vaccine Leads to Higher B-Cell Responses than a Vector Prime/Protein Boost or DNA Prime/Vector Boost Regimens

Slides Unavailable

N Frahm, DP Friedrich, P Walsh, S De Rosa, P Spearman, S Barnett, M Keefer, P Goepfert, H Robinson, B Graham, H Liao, G Tomaras, B Haynes, S Rerks-Ngarm, J Kim, MJ McElrath

OA10.06

15:00 – 16:00

Poster Viewing with Coffee Break

Ballroom B, Level 22

13:30 – 15:00

Oral Abstract Session 11:
Mucosal Immunity

Lotus 5 - 7, Level 22

13:30 - 13:45

Microarray Analysis of Cervical Tissue Reveals a Transcriptional Imprint that Correlates with Protective Immunity in SIV-ΔNef-Vaccinated Animals

Presentation Slides

AJ Smith, SW Wietgrefe, CS Reilly, L Duan, Q Li, M Zeng, AT Haase

OA11.01

13:45 - 14:00

Gut Inflammation and Indoleamine Deoxygenase Inhibit IL-17 Production and Induce Cytotoxicity in RORγt+ NKp44+ Mucosal NK Cells During SIV Infection

Presentation Slides

R Reeves, P Rajakumar, TI Evans, M Connole, J Gillis, Y Kuzmichev, R Johnson

OA11.02

14:00 - 14:15

Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering SIV DNA

Slides Unavailable

SN Gordon, RC Kines, G Kutsyna,   Ma, A Hryniewicz, BF Keele, JN Roberts, C Fenizia,   Hidajat, N Cuburu,  B  Buck, ML Bernardo, M Robert-Guroff,  J Miller, BS  Graham, DR Lowy,  T Schiller, G Franchini

OA11.03

14:15 - 14:30

Durability and Phenotype of SIV-Specific Mucosal T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys

Presentation Slides

H Li, J Liu, A Carville, KG Mansfield, S Clark, D Lynch, DH Barouch

OA11.04

14:30 - 14:45

Role of Genital Tract Inflammation and T Cell Activation in CD4 Depletion at the Female Genital Tract During HIV Infection

Presentation Slides

L Liebenberg, H Jaspan, D Coetzee, A Williamson, J Passmore

OA11.05

14:45 - 15:00

SIV attenuated vaccine-induced plasma cells and antibodies limit infection at the portal of entry and systemically following vaginal challenge

Slides Unavailable

M Zeng, L Duan, Q Li, A Smith, S  Wietgrefe, Pj Southern, CS Reilly, S Pambuccian, L  Shang, PJ Skinner, M Zupancic, M Piatak, Jr, D  Waterman, K Reeves, JD Lifson, P Johnson, AT Haase

OA11.06 LB

15:00 – 16:00

Poster Viewing with Coffee Break

Ballroom B, Level 22

16:00 – 18:00

Symposia 02:
Recent Advances in B Cell and Protective Antibody Responses

Ballroom A, Level 22

16:00 – 16:24

Mucosal Gp41 Antibodies-Mediated Protection from Vaginal SHIV Challenges

Slides Unavailable

Morgane Bomsel
Institut Cochin-Paris Descartes-Inserm U1016 CNRS UMR8104
Paris, France

S02.01

16:24 – 16:48

What is a Protective Antibody Response?

Presentation Slides

Robert Gallo
Institute of Human Virology-University of Maryland School of Medicine
Baltimore, MD, USA

S02.02

16:48 - 17:12

Efficacy of Non-Neutralizing Antibodies in NHP

Slides Unavailable

Robin Shattock
Imperial College London
London, United Kingdom

S02.03

17:12 – 17:36

Developing Broadly Neutralizing Antibodies from Between the Gaps of the Quantized Humoral Immune Response

Presentation Slides

Peter Kwong
National Institutes of Health/NIAID/VRC/SBS
Bethesda, MD, USA

S02.04

17:36 – 18:00

Broad Neutralization Coverage of HIV by Highly Potent Antibodies

Slides Unavailable

Pascal Poignard
International AIDS Vaccine Initiative (IAVI)
New York, NY, USA

S02.05

16:00 – 18:00

Symposia 03:
The Role of Host Genetics in Innate and Adaptive Immunity

Lotus 1 - 4, Level 22

16:00 – 16:24

The Role of the MHC in Adaptive Immunity Against HIV 

Presentation Slides

Mina John
Institute of Immunology and Infectious Diseases
Perth, Australia

S03.01

16:24 – 16:48

Host Genetic Factors That Influence HIV-1 Control

Presentation Slides

Danielle van Manen
Academic Medical Center
Amsterdam, Netherlands

S03.02

16:48 - 17:12

Next Generation Sequencing in HIV Host Genetics

Presentation Slides

Kevin Shianna
Duke University
Durham, NC, USA

S03.03

17:12 – 17:36

Antivial Activity of NK Cells in HIV-1 Infection

Slides Unavailable

Marcus Altfeld
Ragon Institute of MGH, MIT and Harvard
Charlestown, MA, USA

S03.04

17:36 – 18:00

TRIM5 Polymorphism and Experimental Models of HIV Infection and AIDS

Presentation Slides

Welkin Johnson
Harvard Medical School NEPRC
Southborough, MA, USA

S03.05

16:00 – 18:00

Symposia 04:
Integrated and Emerging Novel Issues in Clinical Trials

Lotus 5 - 7, Level 22

16:00 – 16:24

Passive Immunization to Prevent HIV Infection: Potential Applications and Challenges

Slides Unavailable

Barney Graham
Vaccine Research Center, NIH, NIAID
Bethesda, MD, USA

S04.01

16:24 – 16:48

Development of Ibalizumab and Improved Variants for Passive Immunization Against HIV

Presentation Slides

David Ho
Aaron Diamond AIDS Research Center
New York, NY, USA

S04.02

16:48 - 17:12

Challenges in the Design of Future Combination Prevention Trials

Slides Unavailable

Magdalena Sobieszczyk
Columbia University
New York, NY, USA

S04.03

17:12 – 17:36

Regulatory Considerations for the Approval of Novel HIV Vaccine Clinical Trial Designs in a Developing Country

Presentation Slides

Gavin Steel

Management Sciences for Health (MSH)
Pretoria, South Africa

S04.04

17:36 – 18:00

Challenges of Integrating Mucosal Immune Assessments Into HIV Vaccine Trials

Presentation Slides

Aggrey Omu Anzala
Kenya AIDS Vaccine Initiative / University of Nairobi
Nairobi, Kenya

S04.05

17:30 – 19:00

Poster Session 02 and Reception

Ballroom B Level 22

 

All posters ending in even numbers were presented during Poster Session 02.

Thursday, 15 September (back to top)

08:30 – 10:30

Symposia 05:
Systems Biology

Ballroom A, Level 22

08:30 – 08:54

Systems Biology of Dengue Infection

Slides Unavailable

Marcin Kwissa
Emory Vaccine Center, Emory University
Atlanta, GA, USA

S05.01

08:54 – 09:18

Whole Blood Transcriptional Monitoring of Acute HIV-1 Infection Reveals Differential Signatures of Host Immune Activation

Presentation Slides

Jason Skinner
Baylor Institute for Immunology Research
Dallas, TX, USA

S05.02

09:18 – 09:42

Functional Genomic Analysis of the Human
T Cell Response to Chronic Viral Infection

Slides Unavailable

William Haining
Dana-Farber Cancer Institute
Boston, MA, USA

S05.03

09:42 – 10:06

Correlates of Immune Protection: A System Biology Analysis of Vaccine and Natural Mediated Immune Protection

Slides Unavailable

Rafick-Pierre Sekaly
Vaccine & Gene Therapy Institute of Florida
Port St Lucie, FL, USA

S05.04

10:06 – 10:30

Systems Vaccinology: Using the Tools of Systems Biology to Enable Rational Vaccine Design

Presentation Slides

Erica Andersen-Nissen
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

S05.05

08:30 – 10:30

Symposia 06:
New Concepts in Protection Against HIV Acquisitions

Lotus 1 - 4, Level 22

08:30 – 08:54

Harnessing Antibody-Mucus Interactions to Prevent HIV Transmission

Slides Unavailable

Thomas Hope
Northwestern University
Chicago, IL, USA

S06.01

08:54 – 09:18

a4ß7/CD4 T Cells are Key Targets in Mucosal Transmission of HIV

Slides Unavailable

James Arthos 
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, MD, USA

S06.02

09:18 – 09:42

Critical Role of Retinoic Acid and Gut-Tropic Lymphocytes in Intestinal Immune Responses

Presentation Slides

J. Rodrigo Mora
Massachusetts General Hospital, Harvard Medical School
Boston, MA, USA

S06.03

09:42 – 10:06

Defining the Spectrum of Vaccine Induced Humoral Responses

Slides Unavailable

Georgia Tomaras
Duke University
Durham, NC, USA

S06.04

10:06 – 10:30

Correlates of Protection Against SIVmac251 in Vaccinated Rhesus Monkeys

Slides Unavailable

Dan Barouch
Beth Israel Deaconess Medical Center
Boston, MA, USA

S06.05

08:30 – 10:30

Symposia 07
Characterization of Breakthrough Viruses

Lotus 5 - 7, Level 22

08:30 – 08:54

A Deeper Look At The Virus Populations Infecting Step Trial Volunteers

Slides Unavailable

James Mullins
University of Washington
Seattle, WA, USA

S07.01

08:54 – 09:18

Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 Trial

Slides Unavailable

Morgane Rolland        
U.S. Military HIV Research Program, Henry Jackson Foundation
Rockville, MD, USA

S07.02

09:18 – 09:42

Increased Multiple Variant Transmission in VAX003 Injection Drug Users

Presentation Slides

Katharine Bar
University of Alabama at Birmingham
Birmingham, AL, USA

S07.03

09:42 – 10:06

Sieve analysis of RV144

Presentation Slides

Paul Edlefsen
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

S07.04

10:06 – 10:30

Understanding HIV Transmission Utilizing Transmitted/Founder Viruses

Presentation Slides

Brandon Keele
SAIC-Frederick, National Cancer Institute
Frederick, MD, USA

S07.05

10:30 – 11:00

Tea and Coffee Break

Ballroom B, Level 22

11:00 – 12:30

Plenary Session 03:
Novel Immunogens and Vaccine Deliver Strategies: Where Do We Go Next?

Ballroom A, Level 22

11:00 – 11:30

Development of HIV-1 Neutralizing Antibody Vaccines: From Structure to Immunogen Design

Presentation Slides

Jeffrey Boyington
Vaccine Research Center, National Institutes of Health
Bethesda, MD, USA

PL03.01

11:30 – 12:00

Current Status and Future Directions of Vector Based HIV Vaccines

Presentation Slides

C. Richter King
International AIDS Vaccine Initiative
New York, NY, USA

PL03.02

12:00 – 12:30

New Generation of Adjuvants for HIV Vaccines

Slides Unavailable

Steven Reed
Infectious Disease Research Institute
Seattle, WA, USA

PL03.03

12:30 – 13:30

Closing Session 

Ballroom A, Level 22

12:30 – 12:45

Closing Remarks
Pratap Singhasivanon
2011 Conference Chair
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand

 

12:45 – 13:00

AIDS Vaccine 2012
Dan Barouch
2012 Conference Co-Chair
Beth Israel Deaconess Medical Center
Boston, MA, USA